Illumina, Inc. $ILMN Shares Purchased by Cardiff Park Advisors LLC

Cardiff Park Advisors LLC raised its stake in Illumina, Inc. (NASDAQ:ILMN) by 258.3% during the 1st quarter, HoldingsChannel.com reports. The firm owned 6,137 shares of the life sciences company’s stock after acquiring an additional 4,424 shares during the period. Cardiff Park Advisors LLC’s holdings in Illumina were worth $756,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ILMN. Empowered Funds LLC grew its position in shares of Illumina by 113.7% in the 1st quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock valued at $737,000 after buying an additional 4,940 shares during the last quarter. Sivia Capital Partners LLC acquired a new position in Illumina in the second quarter valued at $621,000. CW Advisors LLC acquired a new position in Illumina in the second quarter valued at $275,000. Marshall Wace LLP grew its holdings in shares of Illumina by 49.0% during the second quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company’s stock worth $5,691,000 after purchasing an additional 19,618 shares during the last quarter. Finally, Cresset Asset Management LLC grew its holdings in shares of Illumina by 30.9% during the second quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company’s stock worth $706,000 after purchasing an additional 1,748 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Insider Buying and Selling

In other news, SVP Patricia Leckman sold 783 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $162.59, for a total transaction of $127,307.97. Following the completion of the sale, the senior vice president owned 21,259 shares in the company, valued at $3,456,500.81. This represents a 3.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Scott M. Davies sold 615 shares of the stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $180.00, for a total value of $110,700.00. Following the sale, the insider directly owned 20,953 shares of the company’s stock, valued at approximately $3,771,540. This represents a 2.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 1,003,769 shares of company stock worth $155,710,908. 2.90% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Leerink Partners lifted their target price on Illumina from $175.00 to $210.00 and gave the stock an “outperform” rating in a research report on Friday, July 17th. Wall Street Zen cut Illumina from a “buy” rating to a “hold” rating in a research report on Saturday, July 18th. Piper Sandler raised their price target on Illumina from $170.00 to $200.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 1st. Royal Bank Of Canada started coverage on Illumina in a research note on Thursday, May 14th. They issued an “outperform” rating and a $170.00 price objective for the company. Finally, Barclays increased their price objective on Illumina from $122.00 to $145.00 and gave the company an “underweight” rating in a report on Wednesday, June 24th. Nine analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $156.88.

Illumina Price Performance

Shares of NASDAQ:ILMN opened at $194.09 on Monday. Illumina, Inc. has a one year low of $88.00 and a one year high of $199.14. The stock has a market capitalization of $29.37 billion, a price-to-earnings ratio of 35.29, a PEG ratio of 2.87 and a beta of 1.47. The company has a 50-day simple moving average of $171.24 and a 200-day simple moving average of $145.43. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. The firm had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The business’s revenue was up 4.8% on a year-over-year basis. During the same quarter last year, the company posted $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, analysts predict that Illumina, Inc. will post 5.22 EPS for the current year.

Trending Headlines about Illumina

Here are the key news stories impacting Illumina this week:

• Neutral Sentiment: Illumina was highlighted in a batch of valuation and relative-performance articles comparing it with peers such as Exelixis and Celldex Therapeutics, which may be keeping attention on whether ILMN looks cheap or expensive versus other healthcare names. EXEL vs. ILMN: Which Stock Is the Better Value Option?
• Neutral Sentiment: Analyst sentiment remained middling, with Illumina reported as having an average “Hold” recommendation, suggesting Wall Street is not seeing an immediate reason to aggressively buy or sell the shares. Illumina, Inc. (NASDAQ:ILMN) Given Average Recommendation of “Hold” by Analysts
• Neutral Sentiment: Coverage around Illumina’s role in the Billion Cell Atlas alliance and broader genomics/CRISPR collaboration was noted in commentary on AstraZeneca, but this appears more like a long-term strategic backdrop than a near-term stock mover. AstraZeneca (LSE:AZN) And The Valuation Case Behind Its Drug Pipeline Narrative
• Neutral Sentiment: Short-interest data showed no meaningful change in reported shares outstanding for short positions, so there is no clear evidence here of a new bearish squeeze or panic selling signal.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.